Investigations

Every investigation we've published, newest first — each one built on primary documents and classified under our evidence standard.

Topics Corporations·Government·Institutions·Public Figures·Fraud & Deception·Media
Corporations — 3 September 2024 — 6 min read

Perion Network: The Ad Tech Company the FTC Found Targeting Consumers With Deceptive Advertising Practices

The FTC investigated Perion Network over advertising technology practices it found misrepresented consumers' ability to opt out of tracking and continued to collect behavioral data through mechanisms that ignored or circumvented consumer privacy choices, in violation of the FTC Act's prohibition on deceptive practices.

Read the full report
Corporations — 29 August 2024 — 7 min read

Smith Douglas Homes: The SEC Found the Homebuilder Understated Its Warranty Reserve Liability in Pre-IPO Financial Statements

The SEC charged Smith Douglas Homes with understating its warranty reserve liability in financial statements included in its IPO registration statement — finding the accrued reserve did not adequately reflect the company's historical warranty claims and that the understatement inflated reported net income in the periods before the public offering.

Read the full report
Corporations — 27 August 2024 — 6 min read

Transamerica Life Insurance: The SEC Settlement Over Reserve Calculation Errors That Required $2 Billion in Restatements

The SEC settlement with Transamerica Life Insurance's parent company resolved charges that material weaknesses in the company's actuarial reserve calculation controls resulted in approximately $2 billion in reserve restatements — errors that affected the financial statements investors relied on to assess the company's solvency and capital position.

Read the full report
Corporations — 20 August 2024 — 7 min read

Citius Pharmaceuticals: The SEC Found the Specialty Pharma Company Made Misleading Statements About Phase 3 Trial Design and Powering

The SEC charged Citius Pharmaceuticals with making materially misleading statements about the statistical design and powering of its Phase 3 clinical trial for a hospital-acquired infection treatment, finding investor presentations overstated the trial's scientific rigor and the probability of meeting regulatory approval standards.

Read the full report
Corporations — 14 August 2024 — 7 min read

Bioventus: The Orthobiologics Company the SEC Found Prematurely Recognizing Revenue on Distributor Agreements

The SEC charged Bioventus with recognizing revenue on shipments of its orthobiologics products to distributors before applicable revenue recognition criteria were satisfied, overstating reported revenue and creating a misleading picture of commercial demand that investors used to assess the company's growth trajectory.

Read the full report
Corporations — 8 August 2024 — 7 min read

Dun and Bradstreet: The FTC Found the Business Credit Reporting Giant Failed to Maintain Adequate Accuracy in Its Small Business Credit Files

The FTC found Dun and Bradstreet had failed to maintain reasonable procedures to ensure the accuracy of information in its commercial credit files — errors affecting small businesses' ability to access financing, insurance, and business opportunities based on inaccurate credit data they had no reliable mechanism to identify or correct.

Read the full report